Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Hwoon-Yong Jung, Ph.D
- Phone Number: +82) 02-3010-3197
- Email: hwoonymd@gmail.com
Study Locations
-
-
-
Seoul, South Korea
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Men or women aged ≥ 19 years and ≤ 75 years
- Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization
- Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization
- Subjects who voluntarily signed a consent form
Main Exclusion Criteria:
- Ineligible for upper gastrointestinal endoscopy
- Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization
- Subjects with hypersensitivity to investigational drugs and similar drugs
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DA-5219
administered for 2weeks(DA-5219 + Stillen® Tab placebo)
|
1 tablet/day
3 tablets/day
|
|
Active Comparator: Stillen® Tab
administered for 2weeks(Stillen® Tab + DA-5219 placebo)
|
3 tablets/day
1 tablet/day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement rate of gastric mucosal erosion
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cure rate for gastric mucosal erosion
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
|
Cure rate for gastric mucosal edema
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
|
Improvement rate for gastric mucosal erythema
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
|
Improvement rate for gastric mucosal bleeding
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
|
Improvement rate for gastric subjective symptoms
Time Frame: Change from baseline at 2 weeks
|
Change from baseline at 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DA5219_GAS_III
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.